Lars Fruergaard Jørgensen. How a love story launched the company behind Ozempic, Wegovy Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders ...

When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge Lund, he was expecting an ordinary catchup. advertisement.

Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard ...

Lars Rebien Sørensen has pharmaceutical industry expertise from his 16-year tenure as CEO. In the pre-market trading, 5.37% lesser at $62.60 on the New York Stock Exchange.

If Danes were given to superstition they would be waving every lucky charm going in the direction of Lars Fruergaard Jorgensen. More, they should be giving him daily thanks and checking on his ...

Lars Fruergaard Jorgensen. On the C-SPAN Networks: Lars Fruergaard Jorgensen is a Chief Executive Officer and President for the Novo Nordisk with two videos in the C-SPAN Video Library; the first ...

In this interview Reuters Breakingviews columnist Aimee Donnellan discusses Novo Nordisk's new chapter with Jorgensen, a 30-year company veteran and CEO since 2017. Speakers Lars Fruergaard ...

Lars Fruergaard Jorgensen. Thank you so much. It has past 2 o'clock in Copenhagen. So we thank you all for your interest in Novo Nordisk. And we'll hereby close the half year in this call.

Novo Nordisk CEO, Lars Fruergaard Joergensen talks to the press at Novo Nordisk headquarters in Bagsvaerd, Denmark, Wednesday January 31, 2024.

Lars Fruergaard Jørgensen. So on the Part D access, I think I explained what the dynamics is and it's approximately 10% segment share that's in play here. When we provide our guidance, ...

We’ll send you a myFT Daily Digest email rounding up the latest Novo Nordisk AS news every morning. Lars Fruergaard Jorgensen, incoming chief executive of Novo Nordisk, says the Danish drugmaker ...